Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Gracell Starts China Trial of Donor-Derived CD-19 CAR-T for Leukemia

publication date: Oct 17, 2022

Gracell Biotech, a Suzhou-San Diego CAR-T company, has dosed the first patient in a registrational China Phase II clinical trial of its CD-19 CAR-T candidate for B-cell Acute Lymphoblastic Leukemia (B-ALL). GC007g is Gracell's allogeneic, human leukocyte antigen (HLA)-matched, donor-derived, CD19 CAR-T cell therapy candidate. The trial will enroll B-ALL patients who relapsed after allogeneic human stem cell transplant (allo-HSCT). It will specifically target a subset of patients who cannot contribute immune cells for autologous CAR-T therapy due to poor cell fitness, infections or other conditions. More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital